BioMarin Pharmaceutical Inc
BMRN52.260USD
-0.260-0.50%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
10.04BMarket Cap
19.29P/E TTM
More Details of BioMarin Pharmaceutical Inc Company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
BioMarin Pharmaceutical Inc Info
Ticker SymbolBMRN
Company nameBioMarin Pharmaceutical Inc
IPO dateJul 23, 1999
CEOMr. Alexander Hardy
Number of employees3040
Security typeOrdinary Share
Fiscal year-endJul 23
Address770 Lindaro Street
CitySAN RAFAEL
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94901
Phone14155066700
Websitehttps://www.biomarin.com/
Ticker SymbolBMRN
IPO dateJul 23, 1999
CEOMr. Alexander Hardy
Company Executives of BioMarin Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-7.06%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-7.06%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
221.39M
27.23%
Vimizim
215.42M
26.50%
Naglazyme
128.87M
15.85%
Palynziq
105.94M
13.03%
Aldurazyme
56.44M
6.94%
Other
84.92M
10.45%
By RegionUSD
Name
Revenue
Proportion
United States
272.55M
33.53%
Europe
243.14M
29.91%
Rest of the world
142.74M
17.56%
Latin America
98.12M
12.07%
ALDURAZYME net product revenues marked by Sanofi
56.44M
6.94%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
221.39M
27.23%
Vimizim
215.42M
26.50%
Naglazyme
128.87M
15.85%
Palynziq
105.94M
13.03%
Aldurazyme
56.44M
6.94%
Other
84.92M
10.45%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.84%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.86%
Viking Global Investors LP
6.40%
Other
58.30%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.84%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.86%
Viking Global Investors LP
6.40%
Other
58.30%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.91%
Investment Advisor/Hedge Fund
40.30%
Hedge Fund
7.65%
Pension Fund
3.13%
Research Firm
1.58%
Sovereign Wealth Fund
1.23%
Bank and Trust
1.14%
Individual Investor
0.75%
Venture Capital
0.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1304
191.42M
99.64%
-19.19M
2025Q2
1333
195.10M
101.61%
-16.01M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
18.91M
9.85%
-8.07K
-0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.04M
9.39%
-79.52K
-0.44%
Jun 30, 2025
PRIMECAP Management Company
15.77M
8.21%
-2.00M
-11.26%
Jun 30, 2025
Dodge & Cox
15.11M
7.87%
+153.07K
+1.02%
Jun 30, 2025
Viking Global Investors LP
12.29M
6.4%
+1.49M
+13.78%
Jun 30, 2025
State Street Investment Management (US)
8.85M
4.61%
+384.66K
+4.55%
Jun 30, 2025
AQR Capital Management, LLC
5.58M
2.91%
+2.65M
+90.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.47M
1.81%
+43.19K
+1.26%
Jun 30, 2025
Millennium Management LLC
2.83M
1.48%
+2.16M
+319.74%
Jun 30, 2025
Rothschild & Co Asset Management Europe SCS
1.97M
1.03%
-20.00
-0.00%
Aug 31, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
Invesco Biotechnology & Genome ETF
4.74%
Global X Genomics & Biotechnology ETF
3.43%
First Trust NYSE Arca Biotechnology Index Fund
3.25%
Goldman Sachs Future Health Care Equity ETF
2.85%
SPDR S&P Biotech ETF
2.37%
WealthTrust DBS Long Term Growth ETF
2.11%
Alger Russell Innovation ETF
1.9%
First Trust Health Care Alphadex Fund
1.82%
Pacer Lunt MidCap Multi-Factor Alternator ETF
1.71%
Virtus LifeSci Biotech Products ETF
1.69%
View more
Invesco Biotechnology & Genome ETF
Proportion4.74%
Global X Genomics & Biotechnology ETF
Proportion3.43%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.25%
Goldman Sachs Future Health Care Equity ETF
Proportion2.85%
SPDR S&P Biotech ETF
Proportion2.37%
WealthTrust DBS Long Term Growth ETF
Proportion2.11%
Alger Russell Innovation ETF
Proportion1.9%
First Trust Health Care Alphadex Fund
Proportion1.82%
Pacer Lunt MidCap Multi-Factor Alternator ETF
Proportion1.71%
Virtus LifeSci Biotech Products ETF
Proportion1.69%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
